| Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. | |
| | |
MedLine Citation:
|
PMID: 21892687 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance. Inflammation contributes to the pathophysiology of type 2 diabetes by impairing insulin action in peripheral tissues and via reduction of beta cell function. Inflammation may also play an important role in the development of complications that arise in patients with type 2 diabetes. Hence, the anti-inflammatory actions of commonly used glucose-lowering drugs may contribute, indirectly, to their mechanisms of action and therapeutic benefit. Herein we highlight the anti-inflammatory actions of glucagon-like peptide-1 (GLP-1), which exerts direct and indirect actions on immune function. The observations that GLP-1 receptor agonists exert anti-inflammatory actions in preclinical studies, taken together with case reports linking improvements in psoriasis with GLP-1 receptor agonist therapy, illustrates the emerging clinical implications of non-classical anti-inflammatory actions of incretin-based therapeutics. |
| | |
Authors:
|
D J Drucker; C F Rosen |
Related Documents
:
|
20638037 - Endothelin-1 enhances superoxide and prostaglandin e2 production of isolated diabetic g... 8557237 - Effect of timely insulin administration on pancreatic b-cells of otsuka-long-evans-toku... 2663097 - Regulation of blood glucose by sustained delivery of insulin via alcap ceramics in rats. 12595097 - Decreased activity and impaired induction of nitric oxide synthase by lipopolysaccharid... 9642647 - Carbohydrates as a cerebral metabolic fuel. 9270057 - The absence of synergism between the effects of an aldose reductase inhibitor, epalrest... |
Publication Detail:
|
Type: Comment; Journal Article Date: 2011-09-03 |
Journal Detail:
|
Title: Diabetologia Volume: 54 ISSN: 1432-0428 ISO Abbreviation: Diabetologia Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-10-07 Completed Date: 2012-03-01 Revised Date: 2013-03-19 |
Medline Journal Info:
|
Nlm Unique ID: 0006777 Medline TA: Diabetologia Country: Germany |
Other Details:
|
Languages: eng Pagination: 2741-4 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Ave TCP5-1004, Toronto, ON M5G 1X5, Canada. drucker@lunenfeld.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
complications*,
drug therapy* Female Glucagon-Like Peptide 1 / metabolism* Humans Male Natural Killer T-Cells / metabolism* Psoriasis / complications*, drug therapy* Receptors, Glucagon / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Glucagon; 0/glucagon-like peptide-1 receptor; 89750-14-1/Glucagon-Like Peptide 1 |
| Comments/Corrections | |
Comment On:
|
Diabetologia. 2011 Nov;54(11):2745-54
[PMID:
21744074
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Seasonal influences on population spread and persistence in streams: spreading speeds.
Next Document: The mechanism of hydrogen uptake in [NiFe] hydrogenase: first-principles molecular dynamics investig...